January 31, 2018
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | ESSA Pharma Inc. |
Registration Statement on Form F-3
File No. 333-222654
Ladies and Gentlemen:
ESSA Pharma Inc., a corporation incorporated under the Business Corporations Act (British Columbia), hereby requests, pursuant to Rule 461(a) under the Securities Act of 1933, as amended, that the effective date of the Companys registration statement (the Registration Statement) on Form F-3 (File No. 333-222654) be accelerated by the Securities and Exchange Commission (the Commission) to 4:00 pm, Eastern Time, on Friday February 2, 2018, or as soon thereafter as practicable.
We request that we be notified of such effectiveness by a telephone call to Colin Brown of Skadden, Arps, Slate, Meagher & Flom LLP, the Companys counsel, at (416) 777-4700 and that such effectiveness also be confirmed in writing.
Very truly yours, | ||
ESSA PHARMA INC. | ||
By: | /s/ David Wood | |
Name: David Wood | ||
Title: Chief Financial Officer |